ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet9834ometendo-9834Research ArticleЛекцияLectureДиагностика и лечение эндокринологических осложнений иммунотерапии онкологических заболеванийDiagnosis and treatment of endocrinological complications of immunotherapy of oncological diseaseshttps://orcid.org/0000-0001-6539-466XПигароваЕкатерина АлександровнаPigarovaEkaterina A.

к.м.н.

MD, PhD

kpigarova@gmail.comhttps://orcid.org/0000-0002-0327-4619ДзерановаЛариса КонстантиновнаDzeranovaLarisa K.

д.м.н.

MD, PhD

dzeranovalk@yandex.ruhttps://orcid.org/0000-0001-6876-3336НуралиеваНурана ФейзуллаевнаNuralievaNurana F.

научный сотрудник

MD

dr.nuralievanf@yandex.ruhttps://orcid.org/0000-0002-5634-7877МельниченкоГалина АфанасьевнаMel`nichenkoGalina A.

д.м.н., профессор, академик РАН

MD, PhD, Professor

teofrast2000@mail.ru<p>ФГБУ &laquo;Национальный медицинский исследовательский центр эндокринологии&raquo; Минздрава России</p>Россия<p>Endocrinology Research Centre</p>Russian Federation2018231120181534958Copyright &#x00A9; Пигарова Е.А., Дзеранова Л.К., Нуралиева Н.Ф., Мельниченко Г.А., 20182018Пигарова Е.А., Дзеранова Л.К., Нуралиева Н.Ф., Мельниченко Г.А.Pigarova E.A., Dzeranova L.K., Nuralieva N.F., Mel`nichenko G.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/9834

В этой лекции подробно рассматриваются эндокринопатии, связанные с применением ингибиторов иммунных конечных точек при онкологических заболеваниях, обсуждаются случаи, сроки и особенности клинических проявлений, предлагаются практические рекомендации для лечения пациентов.

In this lecture, we discuss in detail the endocrinopathies associated with the use of immune-checkpoint inhibitors in oncology. The cases, terms and features of clinical manifestations of endocrine-related immune reactions are discussed, and practical recommendations for the treatment of patients are proposed.

ингибиторы иммунных конечных точекипилимумабниволумабэндокринопатииаутоиммунные заболеваниянежелательные явлениятиреоидитгипофизитнадпочечниковая недостаточностьадреналитгипотиреозмеланомарак легкогоimmune-checkpoint inhibitorsipilimumabnivolumabendocrinopathiesautoimmune diseasesadverse effectsthyroiditispituitaryadrenal insufficiencyadrenalitishypothyroidismmelanomalung cancerCTLA-4PD-1Выполнено за счет гранта Российского научного фонда (проект 17-75-30035)ReferencesSpain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat. Rev. 2016;44:51-60. doi: 10.1016/j.ctrv.2016.02.001.Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat. Rev. 2016;44:51-60. doi: 10.1016/j.ctrv.2016.02.001.Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology. 2017;13(4):195-207. doi: 10.1038/nrendo.2016.205.Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology. 2017;13(4):195-207. doi: 10.1038/nrendo.2016.205.Zhao C, Tella SH, Del Rivero J, et al. Anti–PD-L1 Treatment Induced Central Diabetes Insipidus. J. Clin. Endocr. Metab. 2018;103(2):365-369. doi: 10.1210/jc.2017-01905.Zhao C, Tella SH, Del Rivero J, et al. Anti–PD-L1 Treatment Induced Central Diabetes Insipidus. J. Clin. Endocr. Metab. 2018;103(2):365-369. doi: 10.1210/jc.2017-01905.Min L. Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. Genes & Diseases. 2016;3(4):252-256. doi: 10.1016/j.gendis.2016.10.002.Min L. Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. Genes & Diseases. 2016;3(4):252-256. doi: 10.1016/j.gendis.2016.10.002.Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer. 2016;60:190-209. doi: 10.1016/j.ejca.2016.02.025.Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer. 2016;60:190-209. doi: 10.1016/j.ejca.2016.02.025.Weber JS, Kähler KC, Hauschild A. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. J. Clin. Oncol. 2012;30(21):2691-2697. doi: 10.1200/jco.2012.41.6750.Weber JS, Kähler KC, Hauschild A. Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. J. Clin. Oncol. 2012;30(21):2691-2697. doi: 10.1200/jco.2012.41.6750.Iwama S, De Remigis A, Callahan MK, et al. Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. Sci. Transl. Med. 2014;6(230):230ra245-230ra245. doi: 10.1126/scitranslmed.3008002.Iwama S, De Remigis A, Callahan MK, et al. Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. Sci. Transl. Med. 2014;6(230):230ra245-230ra245. doi: 10.1126/scitranslmed.3008002.Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocr. Metab. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocr. Metab. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.Tsiogka A, Jansky GL, Bauer JW, Koelblinger P. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma. Melanoma Res. 2017;27(5):524-525. doi: 10.1097/cmr.0000000000000384.Tsiogka A, Jansky GL, Bauer JW, Koelblinger P. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma. Melanoma Res. 2017;27(5):524-525. doi: 10.1097/cmr.0000000000000384.Wang Z, Zheng Y, Tu Y, et al. Immunological Aspects of Fulminant Type 1 Diabetes in Chinese. Journal of Immunology Research. 2016;2016:1-6. doi: 10.1155/2016/1858202.Wang Z, Zheng Y, Tu Y, et al. Immunological Aspects of Fulminant Type 1 Diabetes in Chinese. Journal of Immunology Research. 2016;2016:1-6. doi: 10.1155/2016/1858202.Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38(4):e55-7. doi: 10.2337/dc14-2349.Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38(4):e55-7. doi: 10.2337/dc14-2349.Win MA, Thein KZ, Qdaisat A, Yeung S-CJ. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. The American Journal of Emergency Medicine. 2017;35(7):1039.e1035-1039.e1037. doi: 10.1016/j.ajem.2017.02.048.Win MA, Thein KZ, Qdaisat A, Yeung S-CJ. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. The American Journal of Emergency Medicine. 2017;35(7):1039.e1035-1039.e1037. doi: 10.1016/j.ajem.2017.02.048.Zhao C, Tella SH, Del Rivero J, et al. Anti–PD-L1 Treatment Induced Central Diabetes Insipidus. J. Clin. Endocr. Metab. 2018;103(2):365-369. doi: 10.1210/jc.2017-01905.Zhao C, Tella SH, Del Rivero J, et al. Anti–PD-L1 Treatment Induced Central Diabetes Insipidus. J. Clin. Endocr. Metab. 2018;103(2):365-369. doi: 10.1210/jc.2017-01905.Дедов И.И., Мельниченко Г.А., Пигарова Е.А., и др. Федеральные клинические рекомендации по диагностике и лечению несахарного диабета у взрослых. // Ожирение и метаболизм. – 2018. – Т.15. – No. 2 – С. 56-71. [Dedov II, Mel'nichenko GA, Pigarova EA, et al. Federal clinical guidelines on diagnosis and treatment of diabetes insipidus in adults. Obesity and metabolism. 2018;15(2):56-71. (in Russ.)] doi: 10.14341/omet9670.Дедов И.И., Мельниченко Г.А., Пигарова Е.А., и др. Федеральные клинические рекомендации по диагностике и лечению несахарного диабета у взрослых. // Ожирение и метаболизм. – 2018. – Т.15. – No. 2 – С. 56-71. [Dedov II, Mel'nichenko GA, Pigarova EA, et al. Federal clinical guidelines on diagnosis and treatment of diabetes insipidus in adults. Obesity and metabolism. 2018;15(2):56-71. (in Russ.)] doi: 10.14341/omet9670.

The authors declare that there are no conflicts of interest present.